CA3234324A1 - Peptide - Google Patents

Peptide Download PDF

Info

Publication number
CA3234324A1
CA3234324A1 CA3234324A CA3234324A CA3234324A1 CA 3234324 A1 CA3234324 A1 CA 3234324A1 CA 3234324 A CA3234324 A CA 3234324A CA 3234324 A CA3234324 A CA 3234324A CA 3234324 A1 CA3234324 A1 CA 3234324A1
Authority
CA
Canada
Prior art keywords
amino acid
peptide
tgf
peptide according
nall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234324A
Other languages
English (en)
French (fr)
Inventor
Yoshinori Suzuki
Masahiko KINEBUCHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptidream Inc
Original Assignee
Peptidream Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptidream Inc filed Critical Peptidream Inc
Publication of CA3234324A1 publication Critical patent/CA3234324A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3234324A 2021-09-30 2022-09-30 Peptide Pending CA3234324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021161353 2021-09-30
JP2021-161353 2021-09-30
PCT/JP2022/036850 WO2023054712A1 (ja) 2021-09-30 2022-09-30 ペプチド

Publications (1)

Publication Number Publication Date
CA3234324A1 true CA3234324A1 (en) 2023-04-06

Family

ID=85780814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234324A Pending CA3234324A1 (en) 2021-09-30 2022-09-30 Peptide

Country Status (10)

Country Link
US (1) US20250034212A1 (https=)
EP (1) EP4410816A4 (https=)
JP (1) JPWO2023054712A1 (https=)
KR (1) KR20240082377A (https=)
CN (1) CN118103387A (https=)
AU (1) AU2022355276A1 (https=)
CA (1) CA3234324A1 (https=)
IL (1) IL311773A (https=)
TW (1) TW202334179A (https=)
WO (1) WO2023054712A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025070720A1 (ja) * 2023-09-29 2025-04-03 ペプチドリーム株式会社 ペプチド
TW202535907A (zh) * 2023-11-10 2025-09-16 日商肽夢想股份有限公司 胜肽、胜肽複合體、醫藥組成物、細胞培養用組成物、以及用於醫療用、診斷用或是研究用之組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
EP1534737A4 (en) * 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
US8188260B2 (en) 2005-12-06 2012-05-29 The University Of Tokyo Versatile acylation catalytic RNAs and uses thereof
MY165160A (en) 2010-09-01 2018-02-28 Genzyme Corp TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
US10882894B2 (en) * 2015-08-11 2021-01-05 Anie Philip Peptidic TGF-beta antagonists
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ

Also Published As

Publication number Publication date
EP4410816A1 (en) 2024-08-07
CN118103387A (zh) 2024-05-28
EP4410816A4 (en) 2025-11-19
US20250034212A1 (en) 2025-01-30
WO2023054712A1 (ja) 2023-04-06
JPWO2023054712A1 (https=) 2023-04-06
IL311773A (en) 2024-05-01
KR20240082377A (ko) 2024-06-10
AU2022355276A1 (en) 2024-05-16
TW202334179A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
WO2015030014A1 (ja) 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法
CN115151556A (zh) 人转铁蛋白受体结合肽
EP4410816A1 (en) Peptide
AU2022242421A2 (en) Peptide and peptide-containing composition
EP3210995B1 (en) Hemagglutinin-binding peptide
CA3228449A1 (en) Human transferrin receptor binding peptide
JP7580120B2 (ja) ヘマグルチニン結合ペプチド
US20250282820A1 (en) Peptide complex having trkb binding activity
JP7854211B2 (ja) ヘマグルチニン結合ペプチド
TW202434613A (zh) 人類運鐵蛋白受體結合肽
AU2024347940A1 (en) Peptide
HK40105341A (zh) 人转铁蛋白受体结合肽
WO2025070720A1 (ja) ペプチド
JP2024523280A (ja) Ｇｈｒ結合ペプチドおよびそれを含む組成物
US20260116920A1 (en) Human transferrin receptor binding peptide
AU2024331192A1 (en) Peptide complex having vegfr -2 agonist activity
HK40105891A (zh) 人转铁蛋白受体结合抗体-肽缀合物
Wen Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides
HK40057758B (zh) 血球凝集素结合肽

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728